FibriCheck vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FibriCheck

by FibriCheck

AVIEW

by Coreline Soft Co.

AI Verdict

FibriCheck specializes in remote heart rhythm monitoring for arrhythmias using smartphone technology, offering tools for both patients and healthcare providers. AVIEW, on the other hand, is an AI platform designed for the analysis of CT scans to detect and monitor lung conditions and assess coronary artery calcification. While both tools contribute to the broader field of cardiology AI, their distinct data sources (smartphone PPG vs. CT scans) and primary applications (rhythm monitoring vs. diagnostic imaging analysis) position them as adjacent rather than direct competitors.

Choose FibriCheck if…

Choose FibriCheck if you need a convenient, smartphone-based solution for continuous or on-demand heart rhythm monitoring, particularly for detecting and managing arrhythmias like Atrial Fibrillation. It is ideal for patients requiring remote oversight of their cardiac health and for healthcare providers seeking to integrate patient-driven data into their monitoring protocols.

View FibriCheck →

Choose AVIEW if…

Choose AVIEW if your clinical practice or radiology department requires advanced AI-powered analysis of CT scans for the early detection, diagnosis, and monitoring of lung cancer, COPD, or coronary artery calcification. This platform excels in providing quantitative metrics, automated segmentations, and comprehensive reports to enhance diagnostic precision and streamline imaging workflows.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FibriCheck	AVIEW
Pricing	Subscription-based, with options for monthly or annual payments. prices vary by region and may be partly or fully covered by insurance or employer.	Subscription; one-off payment
Deployment	Cloud-based (private cloud).	Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FibriCheck

FibriCheck is designed as a patient-facing mobile application that utilizes a smartphone camera for heart rhythm monitoring, making it highly accessible and straightforward for a broad user base. AVIEW, conversely, is an enterprise platform for radiologists, requiring integration with complex hospital systems, which caters to a specialized professional workflow rather than general ease of use.

Clinical Value

AVIEW

Both tools are FDA-cleared and HIPAA compliant, indicating recognized clinical validity. However, AVIEW offers a broader and deeper clinical impact by providing comprehensive AI-driven analysis of CT scans for multiple serious conditions like lung cancer, COPD, and coronary artery calcification, enhancing diagnostic precision for radiologists. FibriCheck focuses on arrhythmia detection via a smartphone, which is valuable for monitoring but less comprehensive in diagnostic scope than AVIEW's capabilities across multiple complex diseases.

Pricing & Value

FibriCheck

FibriCheck provides transparent and publicly available tiered pricing for individual end-users and structured short-term options for doctor-prescribed use, offering clear value propositions. AVIEW's pricing model is enterprise-focused, based on installations and users, and lacks public transparency, likely requiring direct negotiation, which makes its value less immediately discernible for a general comparison.

Enterprise Readiness

AVIEW

AVIEW demonstrates superior enterprise readiness through its explicit mention of workflow automation and integration with PACS/RIS/CIS, along with flexible deployment options including cloud, hybrid, local hardware, and virtualized environments. FibriCheck offers licensing agreements and a professional portal but lacks the deep integration capabilities and diverse deployment options essential for large-scale healthcare enterprise adoption.

Innovation

AVIEW

While FibriCheck's smartphone camera-based PPG technology for heart rhythm measurement is innovative for patient accessibility, AVIEW showcases a broader and deeper level of technical innovation. AVIEW's comprehensive suite of AI-powered features for lung nodule detection and characterization, emphysema quantification, coronary artery calcium scoring, automated segmentation, and 3D visualizations represents advanced AI application in complex medical imaging and diagnostics.

Support & Docs

Tie

Both FibriCheck and AVIEW, as FDA-cleared medical devices, are expected to have robust support and documentation. FibriCheck provides a public-facing help center with user manuals and FAQs for individuals and healthcare providers. AVIEW, as an enterprise solution, would offer professional support channels and technical documentation for integration and clinical use. Without specific comparative details on the quality, responsiveness, or breadth of these resources, it is not possible to definitively determine a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FibriCheck	AVIEW
Primary Function	Medically certified app that helps patients monitor their heart rhythm to detect and monitor arrhythmias using just their smartphone.	AI platform offering comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Company	Qompium nv	Coreline Soft Co.
Supported Medical Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Pulmonology, Radiology
Key Feature: Cardiac Rhythm Monitoring	Smartphone camera-based PPG technology for heart rhythm measurement; AI-powered algorithm for arrhythmia detection and analysis; Detection of Atrial Fibrillation (AFib) and other arrhythmias.	Not specified
Key Feature: Lung Imaging Analysis	Not specified	AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score); Emphysema quantification and low attenuation area (LAA) analysis; Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture).
Key Feature: Coronary Artery Analysis	Not specified	Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification); Automated segmentation of coronary arteries.

Videos

Demos, reviews, and walkthroughs featuring FibriCheck and AVIEW.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the typical workflow integration for each tool within a clinical setting, and how deeply do they integrate with existing EHR or imaging systems?

FibriCheck integrates by providing a patient-facing mobile application for heart rhythm monitoring and a healthcare professional portal for reviewing patient data and customizing monitoring rules. While it facilitates patient data review, the depth of direct EHR integration beyond this portal is not explicitly detailed in the provided information. AVIEW is designed for workflow automation and integrates with existing PACS, RIS, and CIS systems, streamlining the analysis of CT scans for lung and cardiac conditions. It enhances diagnostic precision by providing AI-powered analysis directly within the radiology workflow.

Can you elaborate on the accuracy and sensitivity of each tool's primary diagnostic features, and in what specific clinical contexts would a physician find each most beneficial?

FibriCheck utilizes an AI-powered algorithm for arrhythmia detection and analysis, specifically designed for the detection of Atrial Fibrillation (AFib) and other arrhythmias, providing immediate and actionable results. It is most beneficial for remote patient monitoring in cardiology, family medicine, and internal medicine to detect and track heart rhythm irregularities. AVIEW offers AI-powered capabilities for lung nodule detection and characterization, emphysema quantification, and coronary artery calcium (CAC) scoring from CT scans, enhancing diagnostic precision. Physicians in radiology, pulmonology, and cardiology would find it beneficial for early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery disease.

Beyond the listed specialties, what specific clinical problems or patient populations does each tool uniquely address, making it a strong fit for a particular practice?

FibriCheck uniquely addresses the need for continuous, remote heart rhythm monitoring for patients at risk of or living with arrhythmias, allowing for early detection and management. It is particularly valuable for engaging patients in their own cardiac health management through a user-friendly smartphone application. AVIEW uniquely provides comprehensive, AI-driven analysis of CT scans for multiple conditions, including detailed lung nodule characterization, emphysema quantification, and coronary artery calcium scoring. This makes it a strong fit for practices focused on proactive screening, early diagnosis, and detailed follow-up for lung and cardiac conditions from imaging data.

What is the anticipated learning curve for physicians and their support staff to become proficient with each tool, and what is the typical time-to-value for seeing tangible benefits in patient care or workflow efficiency?

The learning curve for FibriCheck appears low, given its patient-facing mobile app and a healthcare professional portal for monitoring, suggesting ease of use for both patients and providers. The 'immediate and actionable results' imply a quick time-to-value in identifying and acting on arrhythmias. AVIEW, with its comprehensive AI platform for CT analysis, 3D visualizations, and detailed reports, may involve a moderate learning curve for fully utilizing all advanced features. However, its workflow automation and integration with PACS/RIS/CIS are designed to streamline radiology workflows, suggesting a relatively quick time-to-value in improving diagnostic efficiency and precision.

For healthcare systems considering a multi-site rollout, what are the key implementation considerations and scalability features offered by each tool?

FibriCheck, as a cloud-based digital application with a patient app and HCP portal, is inherently designed for scalability and remote access, making it suitable for multi-site deployments focused on remote patient monitoring. Implementation would primarily involve patient onboarding and provider access to the centralized portal. AVIEW offers flexible deployment options including cloud, hybrid, and local solutions on dedicated hardware or virtualized environments, which are crucial for multi-site rollouts with varying IT infrastructures. Its workflow automation and integration with PACS/RIS/CIS facilitate seamless scaling across different locations.